Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Dexlansoprazole from Oranienburg vs Osaka Plants
NCT03131895Phase 1Completed
- Sponsor
- Takeda
- Start
- Apr 2017
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dexlansoprazole in gastroesophageal reflux disease (GERD) and erosive esophagitis (EE) (4 arms), sponsored by Takeda. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-Time Curve to Last Quantifiable Concentration and 1 more. Started Apr 2017; status: completed.
02
Drugs
dexlansoprazole
03
Conditions
gastroesophageal reflux disease (GERD)erosive esophagitis (EE)
Beyond the preview
Go deeper on NCT03131895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03131895.